SecSonar.com

Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma Ltd. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Can-Fite BioPharma Ltd. (CANF) is a Biotechnology company based in IL with a market capitalization of $1.8M. Revenue declined 39.4% year-over-year and free cash flow was negative at -$9M. This page tracks CANF's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

IL · 5 employees · IPO Nov 6, 2012

Valuation

Valuation & price

$3.45 · as of May 26, 2026 · -83.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.32

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$21.00$11.88$2.75Jul 25Dec 25Jul 26Jul 7, 25$20.40Jul 9, 25$20.60Jul 11, 25$20.60Jul 15, 25$21.00Jul 17, 25$21.00Jul 21, 25$20.40Jul 23, 25$20.60Jul 25, 25$19.60Jul 29, 25$14.20Jul 31, 25$13.40Aug 4, 25$13.40Aug 6, 25$13.80Aug 11, 25$14.00Aug 13, 25$13.80Aug 15, 25$13.20Aug 19, 25$12.60Aug 21, 25$13.40Aug 25, 25$13.00Aug 27, 25$13.20Aug 29, 25$12.60Sep 3, 25$13.20Sep 5, 25$13.00Sep 9, 25$13.20Sep 11, 25$13.20Sep 16, 25$13.00Sep 18, 25$13.00Sep 22, 25$12.60Sep 24, 25$12.40Sep 26, 25$12.60Sep 30, 25$12.40Oct 2, 25$12.20Oct 6, 25$12.40Oct 8, 25$11.80Oct 10, 25$10.60Oct 14, 25$9.80Oct 16, 25$10.80Oct 21, 25$10.20Oct 23, 25$9.60Oct 27, 25$9.40Oct 29, 25$8.80Oct 31, 25$8.40Nov 4, 25$8.20Nov 6, 25$8.40Nov 10, 25$8.20Nov 12, 25$7.80Nov 14, 25$7.40Nov 18, 25$7.60Nov 20, 25$6.20Nov 25, 25$6.80Nov 28, 25$7.00Dec 2, 25$7.40Dec 4, 25$6.80Dec 8, 25$6.60Dec 10, 25$6.20Dec 12, 25$5.66Dec 16, 25$5.78Dec 18, 25$5.00Dec 22, 25$4.89Dec 24, 25$3.61Dec 29, 25$3.43Jan 2, 26$4.40Jan 6, 26$3.98Jan 8, 26$4.36Jan 12, 26$4.25Jan 14, 26$4.29Jan 16, 26$4.00Jan 21, 26$4.08Jan 23, 26$4.47Jan 27, 26$4.47Jan 29, 26$4.10Feb 2, 26$4.13Feb 4, 26$4.04Feb 9, 26$4.22Feb 11, 26$4.40Feb 13, 26$4.53Feb 18, 26$4.31Feb 20, 26$4.65Feb 24, 26$4.39Feb 26, 26$4.93Mar 2, 26$4.86Mar 4, 26$6.02Mar 6, 26$4.55Mar 10, 26$4.20Mar 12, 26$3.72Mar 17, 26$3.43Mar 19, 26$3.33Mar 23, 26$3.24Mar 25, 26$3.23Mar 27, 26$3.14Mar 31, 26$3.10Apr 2, 26$3.07Apr 7, 26$3.03Apr 9, 26$2.93Apr 13, 26$2.92Apr 15, 26$3.17Apr 17, 26$3.04Apr 22, 26$2.96Apr 24, 26$2.91Apr 28, 26$2.91Apr 30, 26$3.19May 4, 26$3.32May 6, 26$3.35May 8, 26$3.51May 12, 26$3.39May 14, 26$3.49May 18, 26$3.26May 20, 26$3.46May 22, 26$3.40May 28, 26$3.36Jun 1, 26$3.24Jun 3, 26$3.11Jun 5, 26$3.09Jun 9, 26$2.91Jun 11, 26$2.85Jun 15, 26$2.99Jun 17, 26$3.03Jun 22, 26$3.06Jun 24, 26$2.99Jun 26, 26$2.75Jul 2, 26$3.91
$2.7552-week range$21.00
Loading valuation history…

Fundamentals

Key fundamentals

$1.8M

Market cap

-39.4%

Revenue growth (YoY)

94.1%

Gross margin

-$9M

Free cash flow (USD)

-$8.5M

Net debt

Net cash position

-88.6%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$169.5KFY 2017$844.7KFY 2018$3.8MFY 2019$2.0MFY 2020$763.0KFY 2021$853.0KFY 2022$810.0KFY 2023$743.0KFY 2024$674.0KFY 2025$408.2K
$169.5K$408.2K

Free cash flow by year

2016 → 2025

FY 2016$-8.9MFY 2017$-9.5MFY 2018$-4.2MFY 2019$-10.8MFY 2020$-12.1MFY 2021$-9.9MFY 2022$-10.8MFY 2023$-8.4MFY 2024$-7.6MFY 2025$-9.0M
-$8.9M-$9M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202594.1%
100.0%94.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: —

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingClinical Study ResultsJul 1, 2026Filing
  • 6-K filingPatent Allowance SecuredJun 26, 2026Filing
  • 6-K filingScientific Article PublicationJun 22, 2026Filing
  • 6-K filingConference Participation AnnouncementJun 17, 2026Filing
  • 6-K filingAnnual General Meeting ResultsJun 4, 2026Filing
  • 6-K filingPositive Clinical ObservationJun 2, 2026Filing
  • 6-K filingAnnual General Meeting UpdateMay 28, 2026Filing
  • 6-K filingScientific PublicationMay 18, 2026Filing
  • 6-K filingPhase 2b Study AnnouncementMay 13, 2026Filing
  • 6-K filingPositive Phase 2a DataApr 30, 2026Filing

Questions

Frequently asked questions

What is Can-Fite BioPharma Ltd.'s market cap?

Can-Fite BioPharma Ltd. (CANF) has a market capitalization of $1.8M.

What is CANF's P/E ratio?

A meaningful P/E ratio is not available for CANF — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CANF's price-to-book (P/B) ratio?

CANF trades at 0.32 times book value per share.

Are insiders buying CANF stock?

SEC Form 4 filings show no open-market insider buys at Can-Fite BioPharma Ltd. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

GOVX

GeoVax Labs, Inc.

$2M

AIM

AIM ImmunoTech Inc.

$1.3M

AZTR

Azitra, Inc.

$2.3M

SXTP

60 Degrees Pharmaceuticals, Inc.

$1.2M

NEXR

Nexera Technologies Ltd

$1M

ENSC

Ensysce Biosciences, Inc.

$2.6M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.